Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research.
- Published In:
- Frontiers in medicine, 13, 1763185 (2026)
- Database ID:
- RPEP-15609
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15609APA
Lu, Xinyi; Yang, Li. (2026). Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research.. Frontiers in medicine, 13, 1763185. https://doi.org/10.3389/fmed.2026.1763185
MLA
Lu, Xinyi, et al. "Glucagon-like peptide-1 and dual/triple receptor agonists in the treatment of metabolic dysfunction-associated steatotic liver disease: advances in mechanistic research.." Frontiers in medicine, 2026. https://doi.org/10.3389/fmed.2026.1763185
RethinkPeptides
RethinkPeptides Research Database. "Glucagon-like peptide-1 and dual/triple receptor agonists in..." RPEP-15609. Retrieved from https://rethinkpeptides.com/research/lu-2026-glucagonlike-peptide1-and-dualtriple
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.